Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Hold” by Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received an average rating of “Hold” from the twelve ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $13.1429.

JSPR has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st. Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, UBS Group initiated coverage on Jasper Therapeutics in a report on Monday, March 23rd. They set a “neutral” rating on the stock.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in Jasper Therapeutics by 6,394.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after buying an additional 1,719,602 shares in the last quarter. Acorn Capital Advisors LLC bought a new stake in Jasper Therapeutics in the third quarter worth about $3,291,000. Velan Capital Investment Management LP raised its position in Jasper Therapeutics by 86.1% in the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares in the last quarter. Woodline Partners LP acquired a new stake in Jasper Therapeutics in the 3rd quarter valued at about $2,475,000. Finally, Propel Bio Management LLC acquired a new stake in Jasper Therapeutics in the 3rd quarter valued at about $2,449,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR opened at $0.47 on Wednesday. The stock has a market cap of $13.05 million, a price-to-earnings ratio of -0.14 and a beta of 3.00. Jasper Therapeutics has a 1 year low of $0.42 and a 1 year high of $7.19. The business has a fifty day moving average of $0.83 and a 200-day moving average of $1.28.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. On average, equities research analysts predict that Jasper Therapeutics will post -1.81 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.